We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · January 19, 2022

Recurrent/Metastatic Hormone Receptor Positive Breast Cancer With Visceral Crisis

Written by
Sameer Nasir MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • vinod bhuchar

    Jan 21, 2022

    Combination chemotherapy 


    Jan 22, 2022

    As patient is in visceral crisis and progressed while on endocrine therapy leaves less space for further endocrine therapy with CDK 4/6 inhibitors. Duration of adjuvant hormonal therapy and HR receptor status at progression are also helpful for further discussion. At this point of time I would suggest repeat biopsy and chemotherapy.   

  • Rham Zaki

    Jan 23, 2022

    Commibination chemotherapy 

  • John Miah

    Jan 24, 2022

    Cabazitaxel plus fulvestrant and CDK4/6 inhibitor

  • nedim turan

    Jan 24, 2022

    Combination chemotherapy 

  • Farid Saleh

    Jan 27, 2022

    For aspiration of pleural fluid ? ongoing draining
    ? time between original Dx and metastatic disease ? 
    >12 months 
    Could be for CDK4/6 with fulvestrant

  • May 28, 2022

    Pending Moderator approval.

Further Reading